We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Read MoreHide Full Article
On Jul 5, 2016, we issued an updated research report on San Diego, CA-based Illumina Inc. (ILMN - Free Report) , a company that provides tools and integrated systems for the analysis of genetic variation and function. The stock currently carries a Zacks Rank #4 (Sell).
Intense competition continues to be a major challenge for Illumina in the sequencing, SNP genotyping, gene expression and molecular diagnostics markets with several large players already enjoying significant market share, intellectual property portfolios and regulatory expertise. With substantially greater financial, technical, research and other resources, and larger, more established marketing, sales, distribution and service organization, these companies pose significant threat to the company.
Besides, Illumina faces high expenses related to the development of new products, their launch in various markets and investments in partnerships. Evidently, in recent times, Illumina has been witnessing a substantial rise in operating expenses on account of a higher head count, investments in GRAIL and Helix, as well as development projects like Project Firefly.
These escalating costs have compelled management to adopt a strategy to slow down investments in 2016. Moreover, Illumina’s recent dismal performance in Europe led to a below-par outlook for the company’s operations in the country and a slash in the overall guidance for the remainder of 2016.
On a brighter note, in line with its strategy of expansion through partnerships, Illumina recently inked a partnership with MolecularMD Corporation to co-develop and commercialize sequencing-based companion diagnostics to support biopharma drug development programs.
Illumina recently carved out GRAIL to focus on the cancer screening market. The move is expected to expand the company’s share in the multi-billion dollar oncology space. Besides, it has begun work on the detailed planning necessary to embark on a large-scale clinical trial in 2017 with the goal of demonstrating a stage shift in diagnosis.
Stocks to Consider
Some better-ranked medical stocks are GW Pharmaceuticals plc , ICU Medical, Inc. (ICUI - Free Report) and Nxstage Medical, Inc. . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
On Jul 5, 2016, we issued an updated research report on San Diego, CA-based Illumina Inc. (ILMN - Free Report) , a company that provides tools and integrated systems for the analysis of genetic variation and function. The stock currently carries a Zacks Rank #4 (Sell).
Intense competition continues to be a major challenge for Illumina in the sequencing, SNP genotyping, gene expression and molecular diagnostics markets with several large players already enjoying significant market share, intellectual property portfolios and regulatory expertise. With substantially greater financial, technical, research and other resources, and larger, more established marketing, sales, distribution and service organization, these companies pose significant threat to the company.
Besides, Illumina faces high expenses related to the development of new products, their launch in various markets and investments in partnerships. Evidently, in recent times, Illumina has been witnessing a substantial rise in operating expenses on account of a higher head count, investments in GRAIL and Helix, as well as development projects like Project Firefly.
These escalating costs have compelled management to adopt a strategy to slow down investments in 2016. Moreover, Illumina’s recent dismal performance in Europe led to a below-par outlook for the company’s operations in the country and a slash in the overall guidance for the remainder of 2016.
On a brighter note, in line with its strategy of expansion through partnerships, Illumina recently inked a partnership with MolecularMD Corporation to co-develop and commercialize sequencing-based companion diagnostics to support biopharma drug development programs.
Illumina recently carved out GRAIL to focus on the cancer screening market. The move is expected to expand the company’s share in the multi-billion dollar oncology space. Besides, it has begun work on the detailed planning necessary to embark on a large-scale clinical trial in 2017 with the goal of demonstrating a stage shift in diagnosis.
Stocks to Consider
Some better-ranked medical stocks are GW Pharmaceuticals plc , ICU Medical, Inc. (ICUI - Free Report) and Nxstage Medical, Inc. . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>